In vivo pharmacological characterization of TD-4208, a novel lung-selective inhaled muscarinic antagonist with sustained bronchoprotective effect in experimental animal models

Journal of Pharmacology and Experimental Therapeutics

Volumn 346, Issue 2, 2013, Pages 241-250

  Pulido Rios, M T ^a   McNamara, A ^a   Obedencio, G P ^a   Ji, Y ^a   Jaw Tsai, S ^a   Martin, W J ^a   Hegde, S S ^a  

^a THERAVANCE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIPHENYL 2 YLCARBAMIC ACID 1 [2 [[4 (4 CARBAMOYLPIPERIDIN 1 YLMETHYL)BENZOYL]METHYLAMINO]ETHYL]PIPERIDIN 4 YLESTER; BRONCHODILATING AGENT; GLYCOPYRRONIUM BROMIDE; TD 4208; TIOTROPIUM BROMIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRONCHOSPASM; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DOG; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; DRUG TISSUE LEVEL; DRUG TOLERABILITY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; RAT; SALIVATION;

ACETYLCHOLINE; ADMINISTRATION, INHALATION; ANIMALS; BENZAMIDES; BRONCHOCONSTRICTION; BRONCHODILATOR AGENTS; CARBAMATES; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; GLYCOPYRROLATE; LUNG; MALE; METHACHOLINE CHLORIDE; MUSCARINIC ANTAGONISTS; PILOCARPINE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, MUSCARINIC M1; RECEPTOR, MUSCARINIC M3; SALIVATION; SCOPOLAMINE DERIVATIVES;

EID: 84880439289     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.113.203554     Document Type: Article

References (54)

1. Aas P and Maclagan J (1990) Evidence for prejunctional M2 muscarinic receptors in pulmonary cholinergic nerves in the rat. Br J Pharmacol 101:73-76.
2. Abrams P, Andersson KE, Buccafusco JJ, Chapple C, de Groat WC, Fryer AD, Kay G, Laties A, Nathanson NM, and Pasricha PJ, et al. (2006) Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br J Pharmacol 148:565-578.
3. Barnes PJ (1992) Modulation of neurotransmission in airways. Physiol Rev 72: 699-729.
4. Barnes PJ (1993) Muscarinic receptor subtypes in airways. Life Sci 52:521-527.
5. Barnes PJ (2000) The pharmacological properties of tiotropium. Chest 117(2, Suppl) 63S-66S.
6. Barnes PJ (2004) The role of anticholinergics in chronic obstructive pulmonary disease. Am J Med 117 (Suppl 12A):24S-32S.
7. Barr RG, Bourbeau J, Camargo CA, and Ram FS (2006) Tiotropium for stable chronic obstructive pulmonary disease: A meta-analysis. Thorax 61:854-862.
8. Bloom JW, Yamamura HI, Baumgartener C, and Halonen M (1987) A muscarinic receptor with high affinity for pirenzepine mediates vagally induced bronchoconstriction. Eur J Pharmacol 133:21-27.
9. Brusasco V (2006) Reducing cholinergic constriction: the major reversible mechanism in COPD. European Respiratory Review 15:32-36.
10. Casaburi R, Briggs DD, Jr, Donohue JF, Serby CW, Menjoge SS, and Witek TJ, Jr The US Tiotropium Study Group (2000) The spirometric efficacy of once-daily dosing with tiotropium in stable COPD: a 13-week multicenter trial. Chest 118:1294-1302.
11. Casaburi R, Mahler DA, Jones PW, Wanner A, San PG, ZuWallack RL, Menjoge SS, Serby CW, and Witek T, Jr (2002) A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 19:217-224.
12. Casarosa P, Bouyssou T, Germeyer S, Schnapp A, Gantner F, and Pieper M (2009) Preclinical evaluation of long-acting muscarinic antagonists: comparison of tiotropium and investigational drugs. J Pharmacol Exp Ther 330:660-668.
13. Celli BR (2004) Pharmacotherapy in chronic obstructive pulmonary disease, Marcel Dekkr Inc, New York.
14. Disse B, Reichl R, Speck G, Traunecker W, Ludwig Rominger KL, and Hammer R (1993) Ba 679 BR, a novel long-acting anticholinergic bronchodilator. Life Sci 52: 537-544.
15. Eglen RM, Hegde SS, and Watson N (1996) Muscarinic receptor subtypes and smooth muscle function. Pharmacol Rev 48:531-565.
16. Emala CW, Aryana A, Levine MA, Yasuda RP, Satkus SA, Wolfe BB, and Hirshman CA (1995) Expression of muscarinic receptor subtypes and M2-muscarinic inhibition of adenylyl cyclase in lung. Am J Physiol 268:L101-L107.
17. Gavaldà A, MiralpeixM, Ramos I, Otal R, Carreño C, Viñals M, Doménech T, Carcasona C, Reyes B, and Vilella D, et al. (2009) Characterization of aclidinium bromide, a novel inhaled muscarinic antagonist, with long duration of action and a favorable pharmacological profile. J Pharmacol Exp Ther 331:740-751.
18. Gies JP, Bertrand C, Vanderheyden P, Waeldele F, Dumont P, Pauli G, and Landry Y (1989) Characterization of muscarinic receptors in human, guinea pig and rat lung. J Pharmacol Exp Ther 250:309-315.
19. Gross NJ, Co E, and Skorodin MS (1989) Cholinergic bronchomotor tone in COPD. Estimates of its amount in comparison with that in normal subjects. Chest 96:984-987.
20. Haddad EB, Mak JC, and Barnes PJ (1994) Characterization of [3H]Ba 679 BR, a slowly dissociating muscarinic antagonist, in human lung: radioligand binding and autoradiographic mapping. Mol Pharmacol 45:899-907.
21. Haddad EB, Patel H, Keeling JE, Yacoub MH, Barnes PJ, and Belvisi MG (1999) Pharmacological characterization of the muscarinic receptor antagonist, glycopyrrolate, in human and guinea-pig airways. Br J Pharmacol 127:413-420.
22. Hansel TT, Neighbour H, Erin EM, Tan AJ, Tennant RC, Maus JG, and Barnes PJ (2005) Glycopyrrolate causes prolonged bronchoprotection and bronchodilatation in patients with asthma. Chest 128:1974-1979.
23. Hirshman CA, Lande B, and Croxton TL (1999) Role of M2 muscarinic receptors in airway smooth muscle contraction. Life Sci 64:443-448.
24. Janssen LJ and Daniel EE (1990) Pre- and postjunctional muscarinic receptors in canine bronchi. Am J Physiol 259:L304-L314.
25. Johnson CE (1989) Principles of nebulizer-delivered drug therapy for asthma. Am J Hosp Pharm 46:1845-1855.
26. Jongerius PH, van Tiel P, van Limbeek J, Gabreëls FJ, and Rotteveel JJ (2003) A systematic review for evidence of efficacy of anticholinergic drugs to treat drooling. Arch Dis Child 88:911-914.
27. Kesten S, Celli B, Decramer M, Leimer I, and Tashkin D (2009) Tiotropium Handi- Haler in the treatment of COPD: a safety review. Int J Chron Obstruct Pulmon Dis 4:397-409.
28. Kesten S, Jara M, Wentworth C, and Lanes S (2006) Pooled clinical trial analysis of tiotropium safety. Chest 130:1695-1703.
29. Koumis T and Samuel S (2005) Tiotropium bromide: a new long-acting bronchodilator for the treatment of chronic obstructive pulmonary disease. Clin Ther 27:377-392.
30. Leusch A, Eichhorn B, Müller G, and Rominger KL (2001) Pharmacokinetics and tissue distribution of the anticholinergics tiotropium and ipratropium in the rat and dog. Biopharm Drug Dispos 22:199-212.
31. Littner MR, Ilowite JS, Tashkin DP, Friedman M, Serby CW, Menjoge SS, and Witek TJ, Jr (2000) Long-acting bronchodilation with once-daily dosing of tiotropium (Spiriva) in stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 161:1136-1142.
32. Lu S, Parekh DD, Kuznetsova O, Green SA, Tozzi CA, and Reiss TF (2006) An oral selective M3 cholinergic receptor antagonist in COPD. Eur Respir J 28:772-780.
33. Maesen FP, Smeets JJ, Costongs MA, Wald FD, and Cornelissen PJ (1993) Ba 679 Br, a new long-acting antimuscarinic bronchodilator: a pilot dose-escalation study in COPD. Eur Respir J 6:1031-1036.
34. Maesen FP, Smeets JJ, Sledsens TJ, Wald FD, and Cornelissen PJ; Dutch Study Group (1995) Tiotropium bromide, a new long-acting antimuscarinic bronchodilator: a pharmacodynamic study in patients with chronic obstructive pulmonary disease (COPD). Eur Respir J 8:1506-1513.
35. McNamara A, Pulido-Rios MT, Hegde SS, and Martin WJ (2011) Application of the classical Einthoven model of bronchoconstriction to the study of inhaled bronchodilators in rodents. J Pharmacol Toxicol Methods 63:89-95.
36. McNamara A, Pulido-Rios MT, Sweazey S, Obedencio GP, Thibodeaux H, Renner T, Armstrong SR, Steinfeld T, Hughes AD, and Wilson RD, et al. (2009) Pharmacological properties of TD-6301, a novel bladder selective muscarinic receptor antagonist. Eur J Pharmacol 605:145-152.
37. Oba Y, Zaza T, and Thameem DM (2008) Safety, tolerability and risk benefit analysis of tiotropium in COPD. Int J Chron Obstruct Pulmon Dis 3:575-584.
38. Ogoda M, Niiya R, Koshika T, and Yamada S (2011) Comparative characterization of lung muscarinic receptor binding after intratracheal administration of tiotropium, ipratropium, and glycopyrrolate. J Pharmacol Sci 115:374-382.
39. Potgieter P, Hopkins A, Liu P, Quinn C, Amburgey C, and Moran E (2012) A randomized, crossover study to examine the pharmacodynamics and safety of a new antimuscarinic (TD-4208) in COPD. European Respiratory Society Annual Congress 2012. 9-5-2012. 9-1-9012.
40. Qaseem A, Snow V, Shekelle P, Sherif K, Wilt TJ, Weinberger S, and Owens DK; Clinical Efficacy Assessment Subcommittee of the American College of Physicians (2007) Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline from the American College of Physicians. Ann Intern Med 147:633-638.
41. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, and van Weel C, et al.; Global Initiative for Chronic Obstructive Lung Disease (2007) Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 176:532-555.
42. Ryberg AT, Warfvinge G, Axelsson L, Soukup O, Götrick B, and Tobin G (2008) Expression of muscarinic receptor subtypes in salivary glands of rats, sheep and man. Arch Oral Biol 53:66-74.
43. Sánchez C and Lembøl HL (1994) The involvement of muscarinic receptor subtypes in the mediation of hypothermia, tremor, and salivation in male mice. Pharmacol Toxicol 74:35-39.
44. Sarria B, Naline E, Zhang Y, Cortijo J, Molimard M, Moreau J, Therond P, Advenier C, and Morcillo EJ (2002) Muscarinic M2 receptors in acetylcholine-isoproterenol functional antagonism in human isolated bronchus. Am J Physiol Lung Cell Mol Physiol 283:L1125-L1132.
45. Schulz H and Muhle H (2000) Respiration, in The laboratory rat (Krinke G, ed) pp 323-344, Academic Press, Waltham, MA.
46. Steinfeld T, Pulido-Rios MT, Chin K, King K, Huang JX, Lee TW, Jasper JR, Ji Y, Hegde SS, and Mammen M (2009) In vitro characterization of TD-4208, a lungselective and long-acting muscarinic antagonist bronchodilator (Abstract). Am J Respir Crit Care Med 179:A4553.
47. Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, and Decramer M; UPLIFT Study Investigators (2008) A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 359:1543-1554.
48. (2003) Tiotropium NDA-21-395. FDA CDER Tiotropium NDA-21-395. Pharmacol Rev 021395 (S-000 Part 01): https://www.pharmapendium.com/fda.do? drugName5Tiotropium1Bromide1Monohydrate Accessed April 10, 2013.
49. van Noord JA, Bantje TA, Eland ME, Korducki L, and Cornelissen PJ; The Dutch Tiotropium Study Group (2000) A randomised controlled comparison of tiotropium nd ipratropium in the treatment of chronic obstructive pulmonary disease. Thorax 55:289-294.
50. van Noord JA, Smeets JJ, Custers FL, Korducki L, and Cornelissen PJ (2002) Pharmacodynamic steady state of tiotropium in patients with chronic obstructive pulmonary disease. Eur Respir J 19:639-644.
51. Vestbo J, Hurd SS, Agustí AG, Jones PW, Vogelmeier C, Anzueto A, Barnes PJ, Fabbri LM, Martinez FJ, and Nishimura M, et al. (2013) Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 187:347-365.
52. Viegi G, Pistelli F, Sherrill DL, Maio S, Baldacci S, and Carrozzi L (2007) Definition, epidemiology and natural history of COPD. Eur Respir J 30:993-1013.
53. Vincken W, van Noord JA, Greefhorst AP, Bantje TA, Kesten S, Korducki L, and Cornelissen PJ; Dutch/Belgian Tiotropium Study Group (2002) Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J 19:209-216.
54. Vogelmeier C, Verkindre C, Cheung D, Galdiz JB, Guclu SZ, Spangenthal S, Overend T, Henley M, Mizutani G, and Zeldin RK (2010) Safety and tolerability of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients. Pulm Pharmacol Ther 23:438-444.